Intermediate-dose intramuscular methylprednisolone acetate in the treatment of rheumatic disease.
Treatment with a high-dose, intravenous bolus of methylprednisolone has been reported in numerous cases of rheumatic diseases. The optimal routes of administration, dosage, dosage interval, and other factors are unknown. This report describes uncontrolled clinical observations with a single dose of 320 mg of intramuscular methylprednisolone acetate in patients with rheumatic disease (12 with rheumatoid arthritis, 2 with spondyloarthropathy). This treatment may provide a useful therapeutic adjunct in selected clinical circumstances.
D000328:Adult; D000893:Anti-Inflammatory Agents / Q000008:administration & dosage* / Q000627:therapeutic use; D001172:Arthritis, Rheumatoid / Q000188:drug therapy; D005260:Female; D006801:Humans; D007273:Injections, Intramuscular; D008297:Male; D008775:Methylprednisolone / Q000008:administration & dosage / Q000031:analogs & derivatives* / Q000627:therapeutic use; D000077555:Methylprednisolone Acetate; D008875:Middle Aged; D012216:Rheumatic Diseases / Q000188:drug therapy*; D012446:Sacroiliac Joint; D013166:Spondylitis / Q000188:drug therapy; D013997:Time Factors
D000893:Anti-Inflammatory Agents; D000077555:Methylprednisolone Acetate; D008775:Methylprednisolone